RxDoctor Payments Data

Darwin Jeyaraj, MD

Interventional Cardiology · Joplin, MONPI 1720180433

Payments from drug & device makers

$17,545in general payments, 2019–2025

Across 163 payments — averaging $107.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$3K
  • W. L. Gore & Associates, Inc.$3K
  • Edwards Lifesciences$3K
  • Boston Scientific$2K
  • Angiodynamics, Inc.$1K
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$11,17564%
  • Food & beverage$6,29536%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,545 in reported general payments places this provider in the 55th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$703,978
Medicare patients
2,044
Services billed
8,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan1,133$880,608
EliquisApixaban1,090$835,595
XareltoRivaroxaban374$310,077
JardianceEmpagliflozin361$306,383
FarxigaDapagliflozin Propanediol235$175,984
OzempicSemaglutide140$157,641
Repatha SureclickEvolocumab93$77,061
WegovySemaglutide27$38,535
Praluent PenAlirocumab29$30,208
MounjaroTirzepatide24$29,901
BrilintaTicagrelor53$28,819
VascepaIcosapent Ethyl49$21,653
RybelsusSemaglutide15$16,412
Repatha SyringeEvolocumab19$11,887
ClopidogrelClopidogrel Bisulfate1,461$10,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$880,6081,133 claims
PfizerEliquis$19$835,5951,090 claims
AstraZenecaFarxiga, Brilinta$17$204,803288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →